THE PROCTER AND GAMBLE COMPANY

Lobbying for THE PROCTER AND GAMBLE COMPANY

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $1,320,000.00 expenses · posted Jul 21, 2025

Official filing document

Bills named in this filing 4

HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 2003
Strengthening Benefit Plans Act of 2025
HR 3749
HER Act
HR 4273
Over-the-Counter Monograph Drug User Fee Amendments

Lobbying activity 7

Science/Technology

-H.R. 1 (One Big Beautiful Bill Act - AI Moratorium)

Manufacturing

-Issues related to U.S. Manufacturing

Taxation/Internal Revenue Code

-OECD Digital Tax Project (Global Minimum Tax Implementation) -H.R. 1 (One Big Beautiful Bill Act - Corporate/International Tax Provisions) -S.2003 (Strengthening Benefit Plans Act of 2025)

Trade (domestic/foreign)

-Issues related to IEEPA Tariffs -Issues related to the Pharmaceuticals Section 232 Trade Investigation -Issues related to Lumber Section 232 Trade Investigation

Consumer Issues/Safety/Products

-Issues related to product safety

Health Issues

-Issues related to over the counter drug policy -Issues related to ingredient labeling -H.R. 3749(IH) Health and Endocrine Research on Personal Care Products for Women Act* -H.R.4273 To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes

Chemicals/Chemical Industry

-Issues related to new chemical approvals (no bill)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.